ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Daunorubicin

Also written as “daunorubicin + cytarabine”, “daunorubicin hydrochloride” and “CPX-351 (Cytarabine:Daunorubicin) Liposome Injection”.

Its studies are mostly in Leukemia, Myeloid, Acute · Hematologic Neoplasms, led by 7 companies.

Drug pageDaunorubicin: every studyMany companies study it; this page follows only the 7 they lead. All 104 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Oct 16, 20067 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jazz Pharmaceuticalsits history only10 open or runningphase 1since Oct 16, 2006Oct 16, 2006none ahead
Kanisa Pharmaceuticalsits history only10 open or runningphase 2since Aug 9, 2005Aug 9, 2005none ahead
Kura Oncologyits history only11 open or runningphase 3since May 16, 2025May 16, 2025Nov 2031phase 3 · NCT07007312
Novartis10 open or runningphase 1since Oct 6, 2004Oct 6, 2004none ahead
Pfizerits history only10 open or runningphase 3since Dec 21, 2017Dec 21, 2017none ahead
Sichuan Biokin Pharmaceuticalits history only11 open or runningphase 3since Nov 20, 2025Nov 20, 2025Dec 2027phase 3 · NCT07255872
Sumitomo Pharmaits history only10 open or runningphase 1since Sep 27, 2017Sep 27, 2017none ahead

Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 6, 2004First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT00093600 · 69 enrolled · United States, Germany

TargetBeta

TOP2A →read by rule
“DNA topoisomerase II alpha inhibitor; DNA topoisomerase II alpha inhibitor; DNA inhibitor; DNA inhibitor”ChEMBL 37, by rule

Other programs on TOP2A

ProgramCompanyFurthest phaseStudies
DoxorubicinruleHoffmann-La Rochephase 461
EtoposideruleHoffmann-La Rochephase 328
amrubicinruleBristol-Myers Squibbphase 39

Studies

The one study Novartis leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00093600Leukemia, Myeloid, Acute · United States, Germany1CompletedJun 201169

How it is read

Names in the registry

  • “Daunorubicin”, 4 entries
  • “daunorubicin + cytarabine”, 1 entry
  • “daunorubicin hydrochloride”, 1 entry
  • “CPX-351 (Cytarabine:Daunorubicin) Liposome Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.